title: Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
abstract: Acute akinesia (AA) is a rare but serious complication of Parkinson's Disease (PD) 0,3% of all patients with PD). It can be related to infectious condition, surgery, or treatment changes. AA can completely recover or result in some motor deficits, and, in the most severe forms, it may lead to untreatable complications and death. Here we report the case of a 67-year-old man with PD who rapidly developed a severe akinetic state with rise of temperature (39 degrees C) and creatine phosphokinase concentration (up to 5000 mg/dL). After excluding infection diseases and other pathologies, we suspected AA and added apomorphine 50mg/die s.c. and ondansetron 8 mg i.v. The patient responded to treatment and ameliorated in few weeks.
authors.affiliation: Department of Experimental and Clinical Medicine and Experimental and Clinical Neurosciences, University of Trieste, Strada di Fiume 447, Trieste, Italy. simonetto.marco@gmail.com
authors.forename: Marco
authors.initials: M
authors.lastname: Simonetto
authors.forename: Laura
authors.initials: L
authors.lastname: Ferigo
authors.forename: Luca
authors.initials: L
authors.lastname: Zanet
authors.forename: Livio
authors.initials: L
authors.lastname: Capus
authors.forename: Lucia
authors.initials: L
authors.lastname: Antonutti
authors.forename: Marino
authors.initials: M
authors.lastname: Zorzon
authors.forename: Gilberto
authors.initials: G
authors.lastname: Pizzolato
mesh_terms: D000208:Acute Disease; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000378:metabolism; D001058:Apomorphine / Q000008:administration & dosage; D001480:Basal Ganglia Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D003402:Creatine Kinase / Q000097:blood; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage; D004351:Drug Resistance; D005334:Fever / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D008297:Male; D017294:Ondansetron / Q000008:administration & dosage; D010300:Parkinson Disease / Q000150:complications*; D012131:Respiratory Insufficiency; D012702:Serotonin Antagonists / Q000008:administration & dosage; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D012702:Serotonin Antagonists; D017294:Ondansetron; D003402:Creatine Kinase; D001058:Apomorphine